BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals Announces Secondary Offering

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) watched its shares fall handily on Tuesday after the firm announced a secondary offering. The company plans on selling $80 million of common stock, with ...
Read Full Story »

Top Analyst Upgrades and Downgrades: BioCryst, Exxon, FCA, HPE, IAMGOLD, Mallinckrodt, Rockwell Collins and More

Stocks were indicated to open higher on Wednesday after Tuesday's strong sell-off. The indexes still remain close to all-time highs, and the one trend that has prevailed for more than ...
Read Full Story »

BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win

Shares of BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw a handy gain on Tuesday after the company released the final results from its mid-stage APeX-1 clinical trial in hereditary angioedema (HAE). ...
Read Full Story »
buy sell stocks

Top Analyst Upgrades and Downgrades: BioCryst, Cisco, Groupon, SunPower, Tesla, Wells Fargo and Many More

Stocks took a breather on Thursday after a strong Philadelphia Fed report and a low jobless claims report, but the markets have been hitting all-time highs. The Dow hit 20,600 and ...
Read Full Story »
biotech word cloud

8 Major Biopharma Events Coming Later in 2016 and in 2017

Companies in the pharmaceutical industry generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There can be a fair amount of risk ...
Read Full Story »
biotech word cloud

4 BioPharma Movers That Cannot Be Ignored

Over the past week, a few biotech companies made absolutely massive runs, either up and down. In the past year, the health care sector was on fire from positive trials, ...
Read Full Story »
ThinkstockPhotos-481735362

Is BioCryst Reaching Crush Depth?

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is getting crushed after announcing results from OPuS-2 for the treatment of hereditary angioedema (HAE) attacks. Unfortunately, the company said that this treatment failed to ...
Read Full Story »
refinery

Warren Buffett Continues Massive Energy Insider Buying: Phillips 66, Summit Midstream, Lands’ End and More

Finally after what seems to have been the longest January in recorded investing history, maybe investors are starting to see a light at the end of the tunnel, and it ...
Read Full Story »
French fries

Jefferies Has 5 Top Growth Stocks to Buy After Horrible 2016 Start

Well, last week was lousy, and perhaps some will be recouped this week as the market takes another swing at the upside. One thing's for sure, the massive sell-off last ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

Stocks were pounded lower yet again on Wednesday, but this time on fears of a North Korean hydrogen bomb test. The stock market is off to a rocky start in ...
Read Full Story »
biotech word cloud

4 Key FDA Decisions Expected By Year End

Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount ...
Read Full Story »
Prescription drugs

4 Key FDA Decisions Expected in November and December

Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, as with biotech ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AT&T, BioCryst, Eli Lilly, Facebook, Flextronics, Gap, Tesla and More

Stocks were up yet again on Friday, making for one serious move, with the Dow up about 1,000 points from the lows of just last Friday. Investors have proven over and ...
Read Full Story »
research

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) may be very misunderstood for what it is. The brokerage firm upgraded BioCryst to Neutral and ...
Read Full Story »
biotech

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight. The ...
Read Full Story »